Intrahepatic natural killer cell activation, but not function, is associated with HBsAg levels in patients with HBeAg-negative chronic hepatitis B

Liver International

Volumn 34, Issue 3, 2014, Pages 396-404

  Tjwa, Eric T T L ^a   Zoutendijk, Roeland ^a   van Oord, Gertine W ^a   Biesta, Paula J ^a   Verheij, Joanne ^a,c   Janssen, Harry L A ^a,b   Woltman, Andrea M ^a   Boonstra, Andre ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

HBV; Innate immunity; Liver; NK cells; Viral hepatitis

Indexed keywords

CD45 ANTIGEN; CD69 ANTIGEN; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 18; VIRUS DNA; IFNG PROTEIN, HUMAN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL STIMULATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTE; LIVER BIOPSY; LIVER CELL; LYMPHOCYTE ACTIVATION; MALE; NATURAL KILLER CELL; PHENOTYPE; STAGING; TISSUE SECTION; BLOOD; CELL CULTURE; HEPATITIS B VIRUS; IMMUNOLOGY; LIVER; PATHOLOGY; PHYSIOLOGY; VIRUS REPLICATION;

ADULT; CELLS, CULTURED; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LIVER; LYMPHOCYTE ACTIVATION; MALE; VIRUS REPLICATION;

EID: 84893716133     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12272     Document Type: Article

References (33)

1. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-29.
2. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60.
3. Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 2003; 38: 4-13.
4. Boonstra A, Woltman AM, Janssen HL. Immunology of hepatitis B and hepatitis C virus infections. Best Pract Res Clin Gastroenterol 2008; 22: 1049-61.
5. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8.
6. Norris S, Collins C, Doherty DG, et al. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol 1998; 28: 84-90.
7. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331: 44-9.
8. Mondelli MU, Varchetta S, Oliviero B. Natural killer cells in viral hepatitis: facts and controversies. Eur J Clin Invest 2010; 40: 851-63.
9. Bertoletti A, Maini MK, Ferrari C. The host-pathogen interaction during HBV infection: immunological controversies. Antivir Ther 2010; 15(Suppl 3): 15-24.
10. Tjwa ET, van Oord GW, Hegmans JP, et al. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol 2011; 54: 209-18.
11. Dunn C, Brunetto M, Reynolds G, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007; 204: 667-80.
12. Ahlenstiel G, Edlich B, Hogdal LJ, et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 2011; 141: 1231-9, 9 e1-2.
13. Lok AS, McMahon BJ, Practice Guidelines Committee AASLD. Chronic hepatitis B. Hepatology 2001; 34: 1225-41.
14. Bonorino P, Ramzan M, Camous X, et al. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol 2009; 51: 458-67.
15. Ju Y, Hou N, Meng J, et al. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol 2010; 52: 322-9.
16. Yoo YK, Gavaler JB, Chen K, et al. The effect of recombinant interferon-alpha on lymphocyte subpopulations and HLA-DR expression on liver tissue of HBV-positive individuals. Clin Exp Immunol 1990; 82: 338-43.
17. Peppa D, Micco L, Javaid A, et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog 2010; 6: e1001227.
18. Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009; 49: S13-21.
19. Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011; 8: 275-84.
20. Zhang Z, Zhang S, Zou Z, et al. Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology 2011; 53: 73-85.
21. Newman KC, Riley EM. Whatever turns you on: accessory-cell-dependent activation of NK cells by pathogens. Nat Rev Immunol 2007; 7: 279-91.
22. Tjwa ET, van Oord GW, Biesta PJ, et al. Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B. J Virol 2012; 86: 4102-9.
23. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al.Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-22.
24. Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 2003; 38: 1075-86.
25. Sathaliyawala T, Kubota M, Yudanin N, et al. Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity 2013; 38: 187-97.
26. Moroso V, Metselaar HJ, Mancham S, et al. Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation. Liver Transpl 2010; 16: 895-908.
27. Milich DR, Schodel F, Hughes JL, et al. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J Virol 1997; 71: 2192-201.
28. van der Molen RG, Sprengers D, Binda RS, et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 2004; 40: 738-46.
29. Op den Brouw ML, de Jong MA, Ludwig IS, et al. Branched oligosaccharide structures on HBV prevent interaction with both DC-SIGN and L-SIGN. J Viral Hepat 2008; 15: 675-83.
30. Woltman AM, Op den Brouw ML, Biesta PL, et al. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS One 2011; 6: e15324.
31. Miyagi T, Takehara T, Nishio K, et al. Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection. J Hepatol 2010; 53: 424-30.
32. Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-44.
33. Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011; 55: 1121-31.